The global cluster headache syndrome market size is expected to be USD 948.9 million in 2023. The growing prevalence of neurological and lifestyle-related disorders, external funding for Research and Development, and demand for minimally invasive surgeries are other factors that drive the market growth. The overall demand for cluster headache syndrome treatment is projected to grow at a CAGR of 5.2% between 2023 and 2033, totaling around 1,578.8 million by 2033.
Cluster headache, a neurological disorder, is characterized by severe headaches recurring on one side of the head, usually around the eye. Cluster headache is often accompanied by autonomic symptoms such as excessive tears, swelling of the eye, and nasal decongestion.
In cluster headache syndrome, individuals often suffer from excruciating attacks of unilateral headaches. Some symptoms like migraine, such as sensitivity to light and sound and nausea may also occur with a cluster headache. The causes of cluster headaches are unknown, though some rare causes may be hereditary, smoking, and hypothalamus dysfunction.
| Data Points | Key Statistics |
|---|---|
| Cluster Headache Syndrome Market Value 2023 | USD 948.9 million |
| Cluster Headache Syndrome Market Projected Value (2033) | USD 1,578.8 million |
| Cluster Headache Syndrome Market CAGR (2023 to 2033) | 5.2% |
The intense pain is known to be caused by the dilation of blood vessels, creating pressure on the trigeminal nerve. Diagnosis of cluster headache syndrome can often be misleading, mismanaged, and misdiagnosed. The cluster headache attacks often occur multiple times daily, each lasting not more than three hours without treatment.
The attacks occur daily for several weeks or months and then diminish for a period, though they can last for months or even years in some people. The prevalence of cluster headache syndrome in men is three to four times more than in women. Episodic and chronic are the two types of cluster headaches.
Unlike chronic cluster headaches, the episodic type is characterized by relatively long and pain-free remissions between headaches. About 10 percent of people suffering from cluster headaches have the chronic syndrome. A physical examination of pupils may help doctors detect signs of a cluster headache. For instance, one of the pupils may appear smaller than the other or sag in the eyelid.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global demand for cluster headache syndrome treatment is projected to increase at a CAGR of 5.2% during the forecast period between 2023 and 2033, reaching a total of USD 1,578.8 million in 2033, according to a report from Future Market Insights (FMI). From 2017 to 2022, sales witnessed significant growth, registering a CAGR of 4.5%.
In recent years, there has been a spike in chronic migraines and cluster headache syndrome prevalence. As per WHO’s report, globally, it has been estimated that the prevalence among adults of current headache disorder (symptomatic at least once within the last year) is about 50%. Half to three-quarters of adults aged 18 to 65 years in the world have had headaches in the last year, and among those individuals, 30% or more have reported migraine.
However, the growing investments in research programs to develop effective drugs for treating migraines have boosted the market growth of cluster headache syndrome. During the historic outlook, the market is projected to experience moderate growth, backed by rising awareness and increasing healthcare spending in major regions like North America & Europe.
The increasing prevalence of cluster headache patients with a positive family history enhances the scope of treatment
Although cluster headache is a relatively uncommon primary headache disorder, with a lifetime prevalence of 124 per 100,000 persons, with an annual prevalence rate of 53 per million, it is still a cause for concern across major regions. This is majorly attributed to the prevalence of sedentary lifestyles, which in large part is associated with stressful work environments and extensive durations spent on consumer electronic gadgets. Also, increased television viewing and computer usage have contributed to the growth of cluster headache syndrome.
The rising pervasiveness of cluster headache patients with a positive family history is further anticipated to necessitate the need for treatment for cluster headache syndrome. For instance, according to a research article published by BMC in April 2020, a systematic review and meta-analysis were carried out by the guidelines for preferred reporting items for systematic reviews and meta-analysis protocols (PRISMA- P). It was found that an estimated prevalence of CH patients with a family history was around 6.27%, with an overall I2 of 73%.
While there is no known cure for cluster headaches, doctors and clinicians have prescribed various drug-based and therapeutic treatment approaches to mitigate the incidence of this disorder. Besides, approaches such as administering pure oxygen and triptans have proven highly effective in managing cluster headache syndrome. Furthermore, researchers are studying several potential treatments, including occipital nerve stimulation and deep brain stimulation. These involve implanting electrodes in the brain to send impulses to the occipital nerve and inhibit pain signals.
The absence of Healthcare Experts May Hamper the Market Growth
A shortage of knowledge among healthcare providers, poor public awareness, and government measures to lessen healthcare expenditure are the major barriers to effective care in the cluster headache syndrome market.
Principal Consultant
Exceptional Healthcare Infrastructure & Availability of Specialists in the Region to Propel Market Growth
In terms of geographic divisions, North America is expected to hold the largest share, accounting for 41.2% share in the cluster headache syndrome market in 2023. According to Future Market Insights analysis, the region is projected to maintain its governance over the projection period, backed by flourishing advanced healthcare infrastructure along with the advent of advanced technologies to diagnose the syndrome and the increasing prevalence of migraines.
The increasing approval of novel treatment options for cluster headaches by regulatory authorities, such as the USA Food and Drug Administration (FDA), is driving the growth of the global cluster headache market. For instance, according to the USA FDA News Release, released in June 2019, the USA FDA approved the Emgality (galcanezumabgnlm) solution for injection for the treatment of episodic cluster headaches in adults. Emgality offers patients the first FDA-approved drug that reduces the frequency of episodic cluster headache attacks.
Rising Investments in the Development of New Drugs for Migraines to Push Regional Sales
Based on Future Market Insight’s recent analysis, Europe is the second-largest region in revenue share, accounting for nearly 27.3% share of the cluster headache syndrome market. Rapid economic development in Eastern European countries is expected to accelerate this growth further. Moreover, since obtaining CE approval is easier than obtaining FDA approval, production penetration is relatively higher in this region.
According to PubMed, Cluster headache has a lifetime prevalence of 0.2 to 0.3%. Most headaches are more prevalent in women and somewhat less prevalent in children and youth. Some studies indicate that headache prevalence is increasing during the last decades in Europe. Thereby, several governments are making hefty investments in Research and Development to develop fast-acting drugs or even cure chronic headaches.
Galcanezumab is manufactured by Eli Lilly, who provided funding during the trial. In November 2018, the EU approved galcanezumab in Europe for treating migraine. This drug bonds to a protein called calcitonin gene-related peptide (CGRP), which is identified to play a role in cluster headaches.
Increasing Healthcare Spending to Act as a Principal Growth Driver
According to Future Market Insights, the Asia-Pacific market is anticipated to register rapid growth owing to the increase in the aging population and also the increase in the prevalence of cluster headache syndrome in the geriatric population.
This growth can be attributed to the fact that numerous international manufacturers are shifting their production stations in this region due to unmet medical needs and untapped growth prospects.
Besides, the rapid economic development in emerging countries, such as India and China, and increasing healthcare expenditures are projected to support the market development in the region.
Demand for Corticosteroids to remain most prominent
The global cluster headache syndrome market is bifurcated into drug types and regions. Fast-acting drugs are leading in the global cluster headache market based on the drug type segment. Anti-inflammatory medications called corticosteroids, such as prednisone, are fast-acting preventive drugs that can be effective for several people with cluster headaches.
In case of a recent occurrence or the patient have a pattern of brief cluster headaches in patients, doctors prescribe corticosteroids. The fast-acting drugs are also prescribed if the headache has long remission. Though corticosteroids are considered a good option to consume for several days, some serious side effects such as diabetes, hypertension, and cataracts have been detected in a recent study, which makes them inappropriate for long-term consumption.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 5.2% from 2023 to 2033 |
| Market Value in 2023 | USD 948.9 million |
| Market Value in 2033 | USD 1,578.8 million |
| Base Year for Estimation | 2023 |
| Historical Data | 2017 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Drug type, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East and Africa |
| Key Countries Profiled | United States of America, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, China, Japan, South Korea, India, Australia, Saudi Arabia, South Africa, United Arab Emirates, Israel |
| Key Companies Profiled | AstraZeneca Plc.; Autonomic Technologies Inc.; ElectroCore Medical LLC; GlaxoSmithKline Plc.; Winston Pharmaceuticals Inc.; Zosano Pharma; Eli Lily and Company; Lundback Seattle BioPharmaceutical; Novartis AG; Takeda Pharmaceutical Company Limited |
The market is valued at USD 948.9 million in 2023.
North America with a 41.2% share will dominate the market.
The market is estimated to exhibit a CAGR of 5.2% through 2033.
Calcium channel blockers to drive the market.
The market held a CAGR of 4.5% from 2017 to 2022.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type 5.1. Calcium Channel Blockers 5.2. Corticosteroids 5.3. Sumatriptan 5.4. Lithium Carbonate 5.5. Ergots 5.6. Melatonin 5.7. Anti-Seizure Drugs 5.8. Local Anesthetics 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 6.1. North America 6.2. Latin America 6.3. Western Europe 6.4. Eastern Europe 6.5. South Asia and Pacific 6.6. East Asia 6.7. Middle East and Africa 7. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Key Countries Market Analysis 15. Market Structure Analysis 16. Competition Analysis 16.1. AstraZeneca Plc. 16.2. Autonomic Technologies Inc. 16.3. ElectroCore Medical LLC 16.4. GlaxoSmithKline Plc. 16.5. Winston Pharmaceuticals Inc. 16.6. Zosano Pharma 16.7. Eli Lily and Company 16.8. Lundback Seattle BioPharmaceutical 16.9. Novartis AG 16.10. Takeda Pharmaceutical Company Limited 17. Assumptions & Acronyms Used 18. Research Methodology
Explore Healthcare Insights
View Reports
Cluster Headache Syndrome Market
